Regulatory · Reviewed 2026-06-04

FDA Semaglutide Compounding Update 2026

The FDA has moved to close the last pathway for large-scale compounding of semaglutide. Here is what changed and what it means for online programs.

Quick Answer

On April 30, 2026, the FDA proposed excluding semaglutide (along with semaglutide and liraglutide) from the 503B bulks list, finding no clinical need for outsourcing facilities to compound it from bulk drug substances. With the semaglutide shortage already resolved in 2025, this proposal — if finalized — would remove the main remaining route for industrial-scale compounding. Patient-specific 503A compounding operates under a separate framework.

Key Facts

The proposal was announced April 30, 2026 and published in the Federal Register on May 1, 2026 (Docket FDA-2018-N-3240).
The FDA found no demonstrated clinical need for outsourcing facilities to compound these GLP-1s from bulk substances.
Public comments are due by the deadline in the Federal Register notice (June 30, 2026; some secondary sources cite June 29) before a final determination.
Semaglutide was added to the FDA shortage list in 2022 and removed in 2025; removing it from the bulks list closes the remaining bulk-compounding pathway.
The FDA has separately sent warning letters to telehealth firms over claims that compounded GLP-1s are identical to branded drugs.

What this means for buyers: The rules are tightening, and a final rule may follow the comment period. No provider can guarantee uninterrupted compounded supply. Treat unusually low or “guaranteed” offers with caution and confirm the pharmacy and active form.

Primary sources

FDA press announcement (April 30, 2026): fda.gov
Federal Register notice (May 1, 2026): federalregister.gov

What to Verify

The current status of the proposal — it may be finalized after the comment period.
Whether a given program relies on 503A patient-specific or 503B outsourcing-facility compounding.
That any provider claims are consistent with FDA guidance (no “identical to branded” or guarantee language).

Bottom Line

The direction of travel in 2026 is toward sharply limiting large-scale semaglutide compounding. Follow the FDA docket for the final determination, confirm any program’s pharmacy pathway, and decide with a licensed prescriber. See also our 503A vs 503B explainer.

Compounded semaglutide is not FDA-approved as a finished drug product. Compounded medications may be prescribed only when clinically appropriate and must be evaluated by a licensed prescriber. Branded medications such as Wegovy and Ozempic are FDA-approved products; compounded semaglutide is different and should not be described as FDA-approved, “generic Wegovy,” or “generic Ozempic.”